Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
Sonnet BioTherapeutics Holdings Inc. develops immunotherapeutic biologic drugs for oncology using its FHAB Fully Human Albumin-Binding platform. The platform uses a fully human single-chain antibody fragment designed to bind human serum albumin and transport large-molecule therapies toward tumor and lymphatic tissue, supporting constructs that include cytokines, peptides, antibodies and vaccines.
Company news centers on clinical and regulatory updates for targeted oncology programs, including SON-1010 or IL-12-FHAB in solid tumors and platinum-resistant ovarian cancer, as well as scientific conference presentations, shareholder voting matters, financing activity, capital-structure disclosures and governance developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) reported progress in its Phase 1 clinical trials for SON-1010, an immunotherapeutic drug. The company is enrolling the final dose cohort for the cancer trial (SB101) which has dosed 15 patients, with 36% showing clinical benefit based on stable disease results. No dose-limiting toxicities were observed, and adverse events were mostly mild and transient. SON-1010 demonstrated a prolonged half-life, with pharmacokinetic data suggesting effective targeting of tumors. The next steps include investigating SON-1010's impact on platinum-resistant ovarian cancer. Sonnet's current financial position allows for operational activities into 2024. A webinar discussing these results is scheduled for today at 5 pm ET.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN), a clinical-stage biopharmaceutical firm, announced a webcast on April 18, 2023, at 5:00 pm ET to present data from its SB101 study with SON-1010 involving oncology patients (NCT05352750). Presenters include Richard Kenney, M.D. and Pankaj Mohan, Ph.D.. The webcast will offer a detailed overview of the clinical trial and will be available for later access on the company's website. Also, a poster presentation titled Clinical development of a novel form of interleukin-12 will occur during the AACR 2023 Annual Meeting on April 18, from 1:30 pm to 5:00 pm ET. Sonnet's FHB technology aims to enhance the efficacy of immunotherapeutic drugs by targeting tumor tissues effectively, which is essential for its ongoing clinical applications.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced it will present data from the SB101 multiple-dose clinical trial of SON-1010 (IL12-FHAB) at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The presentation, titled "Clinical development of a novel form of interleukin-12 with extended pharmacokinetics," is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM. SON-1010 is designed for treating adult patients with advanced solid tumors and utilizes FHAB technology for improved targeting of tumor and lymphatic tissues. This marks a significant step in Sonnet's commitment to advancing oncology treatments.